Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

Ruth Brown (), Sean Stern, Sujith Dhanasiri and Steve Schey

The European Journal of Health Economics, 2013, vol. 14, issue 3, 507-514

Abstract: LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment. Copyright Springer-Verlag 2013

Keywords: Lenalidomide; Multiple myeloma; Cost effectiveness; Dexamethasone; Patient access scheme; I13 (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-012-0395-6 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:14:y:2013:i:3:p:507-514

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-012-0395-6

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().